Fam

Quick links to important sections

Fam

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fam

Quick Facts

Property Description
Active Ingredient Ketorolac tromethamine
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Origin Synthetic organic compound
Primary Forms Tablet, injectable solution, nasal spray, ophthalmic solution
General Purpose Powerful, short-term pain relief (analgesia)

What Type of Medicine is Fam?

The medicine Fam is a preparation containing the active ingredient Ketorolac tromethamine, which is internationally recognized as a potent member of the Non-Steroidal Anti-Inflammatory Drug (NSAID) pharmacological class. As a synthetic organic compound, Ketorolac is structurally categorized as an acetic acid derivative. This places it within a subgroup of NSAIDs that are clinically recognized for exhibiting a powerful analgesic effect, which often exceeds its primary anti-inflammatory action at standard therapeutic levels. Ketorolac is noted for its high analgesic efficacy and its established role in managing moderate to severe pain.

Composition and Available Forms of Ketorolac

Ketorolac tromethamine is the sole active ingredient in Fam, making it a single-ingredient product designed for diverse patient needs. The drug is presented in several high-level dosage forms, including the oral tablet, an injectable solution (for intravenous or intramuscular use), a nasal spray, and an ophthalmic solution (eye drops). The availability of these forms ensures that the drug's powerful action can be delivered efficiently, either systemically or locally. Ketorolac's chemical structure allows for these varied routes of administration, providing flexibility for this formulation in clinical settings.

What is the General Purpose of Fam?

The general therapeutic purpose of Fam is to provide rapid and powerful analgesia (pain relief) and complementary anti-inflammatory action for short-term discomfort management. It is often employed in situations where significant, short-duration pain control is necessary, such as after minor surgical procedures or in acute musculoskeletal injury. It achieves this by efficiently disrupting the pain and inflammation signaling process, specifically by inhibiting the production of prostaglandins—chemical messengers that trigger pain and swelling. Its unique potency among NSAIDs makes it a valuable choice for rapid, effective pain control.

What side effects are possible with Fam?

Possible Side Effects and Safety Information

Ketorolac tromethamine (Fam) is associated with an official safety profile defined by the risk of serious adverse reactions, as documented by regulatory bodies. The risk of these serious events, particularly those affecting the gastrointestinal and cardiovascular systems, is generally noted to increase with the duration of use and higher doses. For all systemic formulations (e.g., injection, tablet, nasal spray), the official label mandates that the total combined duration of use must not exceed five days.

Serious Adverse Reactions and Systemic Risk

Government regulatory documents highlight the potential for serious, sometimes fatal, events. These include gastrointestinal adverse events, such as ulceration, bleeding, and perforation of the stomach or intestines. Additionally, the label notes the risk of serious cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke, which may occur early in the course of treatment. Rare, but serious, reactions involving the skin (Stevens-Johnson syndrome) and kidneys (acute renal failure) are also documented.

Common Side Effects and Organ Systems Affected

Adverse reactions are formally classified across several System-Organ Classes. Common side effects frequently listed in regulatory documents involve the gastrointestinal system (nausea, dyspepsia, abdominal pain) and the nervous system (headaches, dizziness, drowsiness).

Safety Considerations for Specific Populations

Safety information includes explicit restrictions for certain patient groups. Use is contraindicated for individuals with advanced renal impairment or pre-existing active peptic ulcer disease. Older adults are generally noted to be at a greater risk for serious gastrointestinal adverse events, and the medication is contraindicated for use during labor and delivery and in nursing mothers.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory documents for Fam (Ketorolac tromethamine) define the overdose profile by its documented clinical manifestations and the clear mandate to seek immediate medical attention for all suspected overdoses.

Documented Overdose Manifestations

Symptoms following acute overdose are generally limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain. Single large overdoses are also associated with abdominal pain and hyperventilation.

Severe Outcomes and Emergency Action

Overdose carries a documented risk of serious or life-threatening outcomes, including gastrointestinal bleeding, acute renal failure, and, rarely, coma or respiratory depression. Because no specific antidotes are known, management relies entirely on symptomatic and supportive care, as officially required.

For patients seen within four hours of a large oral overdose (typically classified as 5 to 10 times the usual dose), official treatment guidance may recommend procedures such as the administration of activated charcoal.

Classification Official Regulatory Statement
Immediate Action Seek immediate medical attention for all suspected overdoses.
Antidote Status No specific antidotes are documented.
Management Focus Symptomatic and supportive care is required.

Therapeutic Uses of Fam

What Fam Treats: Main Uses and Benefits

Fam (Ketorolac) provides support against symptoms related to physical discomfort, focusing on providing essential short-term symptomatic support for conditions marked by increased discomfort or tension. The key benefit is offering symptomatic relief that helps ease the overall symptom burden. The medication is used for the management of moderately severe pain in adults, frequently within the context of postoperative care.


Key Therapeutic Domains

Fam is primarily applied in clinical settings that involve acute or disruptive symptom patterns, where patients experience moderately severe to severe pain, typically stemming from postoperative recovery or musculoskeletal trauma. It contributes to easing the overall symptom load during these phases. It is also commonly used across conditions presenting with acute episodes that manifest as intense, episodic crises, such as renal colic and acute migraine attacks. Furthermore, in ophthalmology, it helps address symptoms like pain, burning, and inflammation following specific procedures, such as cataract surgery, and is applied to manage the pronounced ocular itching associated with seasonal allergies.


Quick Fact: Relief for Acute Discomfort

Symptom Focus Application Context Key Benefit
Moderately Severe Pain Postoperative, Acute Injury, Colic Helps ease the overall symptom load
Localized Ocular Symptoms Post-surgery, Seasonal Allergic Itching Provides supportive relief when symptoms interfere with routine activities

Regulatory References

  1. NIH MedlinePlus overview on Ketorolac Injection

Eligibility and Restrictions for Use

Famotidine, commonly referred to as Fam, is generally used to treat and prevent gastrointestinal conditions related to excess stomach acid. Determining who can safely use this medication requires consideration of individual medical history and other current treatments.

Who Can Use Fam

Famotidine is indicated for adult patients and children weighing 40 kg or more for conditions such as:

  • Peptic ulcers (gastric or duodenal)
  • Gastroesophageal Reflux Disease (GERD)
  • Erosive esophagitis
  • Conditions causing overproduction of stomach acid, like Zollinger-Ellison syndrome.

Appropriate doses may be determined by a healthcare provider for children weighing less than 40 kg.


Who Should Not Use Fam (Contraindications)

Famotidine is contraindicated (should not be used) in patients with a known hypersensitivity or allergic reaction to famotidine or other H2-receptor antagonists (such as cimetidine or ranitidine).

Caution is advised for specific patient groups due to an increased risk of side effects or altered drug clearance. A healthcare provider must assess the benefit-risk ratio in these cases:

Patient Group Consideration
Elderly patients May experience central nervous system side effects (e.g., confusion) more frequently, especially with kidney impairment.
Patients with moderate to severe kidney disease Dosage adjustment is often required, as the medication is eliminated more slowly from the body.
Pregnant or breastfeeding women Use only if clearly necessary, as risk to the fetus or infant has not been definitively established and should be weighed against potential benefits.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Fam (Ketorolac tromethamine), a potent NSAID, is defined by regulatory documents based on risks related to bleeding, altered drug clearance, and effects on renal function. The information below reflects explicit statements found in official government labeling.

Formally Contraindicated Combinations

Co-administration of Fam is officially prohibited with specific substance classes due to a documented high risk of adverse outcomes:

  • Other NSAIDs and Aspirin: Contraindicated due to the cumulative risk of gastrointestinal bleeding and ulceration.
  • Anticoagulants: Prohibited due to a significantly increased risk of serious bleeding.
  • Probenecid: Prohibited because it is documented to increase Fam's plasma levels (AUC and Cmax) and prolong its half-life, creating a toxicity risk.

Documented Pharmacodynamic and Exposure Interactions

Other clinically significant interactions are described in official labeling, primarily concerning additive effects or altered exposure:

Interacting Medicine Documented Interaction Effect
ACE Inhibitors/ARBs May reduce their anti-hypertensive effect and increase the risk of renal impairment.
Diuretics (e.g., Furosemide) NSAIDs can reduce their documented natriuretic (salt-excreting) effect.
Methotrexate, Digoxin Fam may reduce the renal clearance of these drugs, potentially raising their plasma concentrations.
SSRIs, Antiplatelet Agents Increased risk of gastrointestinal bleeding.

Product-Specific Notes

The oral tablet form, when taken with a high-fat meal, is documented to delay and reduce the achievement of its peak plasma concentration. Official labels note that the risk of serious adverse reactions, particularly bleeding, is heightened in elderly patients and those with severe renal impairment.

Mechanism of Action

How Fam Works: Pharmacodynamic Mechanism

Fam's mechanism is defined by the non-selective inhibition of the Cyclooxygenase (COX) enzyme family (COX-1 and COX-2). The molecule functions as a competitive blocker, occupying the enzyme's active site and thus interrupting the fundamental biochemical cascade that converts arachidonic acid into various prostaglandins.

This molecular action results in the suppression of prostaglandin synthesis, which modulates the body's nociceptive signal sensitization. The mechanism operates via a dual action, reducing prostaglandin-mediated sensitization of nerve endings at the peripheral site of activity and dampening signal transmission within the central nervous system.

This mechanism leads to the attenuation of pain signaling without engaging pathways associated with consciousness or opioid reward systems. However, the non-selective inhibition of constitutive COX-1 results in physiological constraints. This action temporarily affects homeostatic processes, including the synthesis of Thromboxane for platelet aggregation and local prostaglandin generation necessary for the maintenance of renal blood flow under physiological stress.

Dosage and Administration Information

How Fam is used

The administration of Fam (Ketorolac tromethamine) is highly structured and determined by the specific form and clinical context. The medicine is administered through several routes, including Intravenous (IV) injection, Intramuscular (IM) injection, and Oral tablets, alongside specialized local delivery methods such as Topical Ophthalmic solution and Intranasal spray.


Systemic Administration Rules

Systemic use—involving the IV, IM, and Oral routes—is governed by a strict time limit. The total combined duration of therapy using these systemic forms must not exceed 5 days for acute treatment. The Oral tablet is specifically designated for continuation therapy and is used only after treatment has been initiated with the parenteral (IV or IM) injection, defining the sequence of acute care.

Standard dosing for a healthy adult typically involves 30 mg every six hours for the injection, with a maximum daily limit of 120 mg. Conversely, patients aged 65 years or older, those weighing under 50 kg, or those with renal impairment require a reduced dose, often resulting in a lower maximum daily limit of 60 mg. Administration also requires specific technique; for example, an IV bolus must be administered over a period of no less than 15 seconds.

Recent Clinical Evidence

Fam: Recent Clinical Evidence


Evidence for Use in Acute Postoperative Pain

Fam was evaluated in research exploring outcomes related to physical discomfort that follow surgical procedures. Research in this area primarily consists of high-quality Randomized Controlled Trials (RCTs), with multiple systematic reviews and meta-analyses compiling the data. These studies focused primarily on Adults and were designed to observe responses over defined time intervals in acute settings.

The research examined several specific outcomes. Studies report how symptoms evolved in the observed populations, noting data show patterns related to a reduced amount of opioid medication consumption. Research also examined whether the treatment was associated with outcomes related to the length of hospital stay. Evidence is primarily focused on short-term results, and follow-up durations were limited (typically up to five days).


Evidence for Use in Acute Musculoskeletal Pain and Crises

Research was studied for its use in conditions associated with acute or disruptive episodes, such as moderately severe acute low back pain or other episodic pain crises. The evidence primarily comes from Randomized Controlled Trials, where researchers often designed studies to compare Fam with a standard comparator. The main variables studied included changes in pain intensity scores and outcomes reflecting daily functioning.

Some analyses noted evidence quality varies across studies due to heterogeneity (variability) in the types of acute pain examined. The research largely explored short-term symptom changes, and data are still emerging regarding outcomes for chronic conditions or preventing symptom recurrence. Results apply only to the populations studied.


Studies in Specific Patient Populations

Research has explored the use of Fam in populations other than typical adults. Specific studies was evaluated in research exploring how symptoms change over time in Older Adults (65 years and over). However, data for certain groups remain insufficient; for example, evidence is limited for usage and specific observed outcomes in pediatric populations (children 6–17 years).

Key Studies & References

  1. The role of ketorolac in multimodal analgesia and opioid-sparing strategies for postoperative pain
  2. Ketorolac Injection (MedlinePlus Drug Information) - U.S. National Library of Medicine

Frequently Asked Questions (FAQ)

Common questions about Fam (FAQ)

Q: Is Fam considered a common or specialized type of medicine?

A: Official information describes Fam as a potent Non-Steroidal Anti-Inflammatory Drug (NSAID). Due to its strength, it is primarily used for the short-term treatment of moderately severe acute pain. This use is generally reserved for discomfort that is typically not managed effectively by less potent non-prescription pain relievers.

Q: How quickly can I expect to see an effect after starting Fam?

A: According to pharmacokinetic studies, the peak pain-relieving effect of the medication can be expected rapidly. This effect typically occurs within 30 to 60 minutes after the medicine is administered. The exact timing may vary slightly depending on the specific formulation being used.

Q: Is it true that Fam can affect my ability to drive?

A: Regulatory documents list dizziness and drowsiness as potential side effects of Fam. Because these effects can impact coordination and judgment, official information notes that patients should be cautious about driving or operating complex machinery until they understand how the medication affects them.

Q: Why is it recommended to follow a particular diet while using Fam?

A: The recommendation to take the oral tablet with food or a meal is based on safety considerations. Official labeling advises this method to help prevent stomach irritation and lessen the potential for gastrointestinal upset.

Q: Is it normal to feel a change in energy levels when first starting Fam?

A: Official reports of adverse reactions include central nervous system effects such as somnolence (drowsiness), malaise (general discomfort), and asthenia (lack of energy/weakness). These documented effects may be perceived by a user as a change in energy level.

Q: Can Fam cause sensitivity to sunlight?

A: Yes, regulatory documents note that photosensitivity is a documented adverse reaction associated with this medication. This means that the skin may have an increased sensitivity to the sun or other sources of UV light while using Fam.

Q: What does it mean if an official document mentions 'contraindications' for Fam?

A: A contraindication is a clear statement in official documents that the medicine must not be used in specific situations or for certain patient groups. This prohibition is established because the potential for harm in those circumstances is unacceptable.

Q: What are the most common reasons a doctor might prescribe Fam?

A: The primary use, as stated in regulatory documents, is the short-term management of moderately severe acute pain. This is typically prescribed for situations like managing discomfort after surgical procedures, where high-level pain control is needed temporarily.

Q: Is there a generic version of Fam available?

A: Yes, the active ingredient in Fam, which is Ketorolac tromethamine, is widely available in generic formulations.

Q: Does Fam have any known effects on mental clarity or mood?

A: Regulatory adverse reaction reports list several effects on the nervous system and mood. These include documented instances of confusion, anxiety, depression, abnormal dreams, and difficulty concentrating.

Q: What kind of studies have been conducted on the long-term use of Fam?

A: Studies and regulatory documents focus on short-term use, as the total combined duration is mandated not to exceed five days. Long-term administration is officially discouraged due to a greater, documented risk of serious side effects, particularly affecting the gastrointestinal and cardiovascular systems.

Q: Why might the instructions for taking Fam change over time?

A: Instructions may change over time because the dose is determined by specific patient characteristics. Regulatory guidelines require dosage adjustments based on factors like the patient’s age, weight, or changes in kidney function to manage the potential for adverse events.

Q: Can taking Fam affect the results of certain lab tests?

A: Official labeling notes that the medication may cause transient changes in the results of certain laboratory tests. These changes may include temporary elevations in markers like liver enzyme levels, blood urea nitrogen (BUN), and creatinine, which are used to monitor organ function.

Q: Does Fam need to be taken consistently every day for it to work?

A: The use of Fam is strictly for short-term, acute pain management and is prescribed on a consistent schedule, such as every four to six hours. The medication's effectiveness throughout the limited treatment period relies on adherence to the prescribed timing.

Q: What does 'potential for a drug interaction' with alcohol mean for Fam?

A: Regulatory sources note that the use of Fam with alcohol is a combination to be avoided. This is because the combination can lead to an increased risk of side effects, specifically raising the potential for stomach bleeding and increasing the possibility of dizziness.

Q: Is it safe to stop taking Fam suddenly?

A: Because Fam is an NSAID and not a narcotic, it is not habit-forming and does not cause dependence. As a result, it is typically intended to be stopped after the specified, short course of treatment is completed.

Q: Is Fam typically prescribed by a general practitioner or a specialist?

A: Due to its high potency and indication for moderately severe pain, the initial administration is often started in a hospital or acute care setting by a specialist. The continuation therapy (such as the oral tablet) may then be managed by various healthcare providers outside the hospital.

Q: What are the possible risks of combining Fam with herbal remedies?

A: Official documents warn against combining Fam with any agents that affect hemostasis (the process of blood clotting). Regulatory information notes the importance of disclosing all concurrent medications, vitamins, and herbal products to a healthcare provider due to the potential for unknown or unstudied risks.

Q: Does Fam require special monitoring or follow-up tests?

A: Official prescribing information recommends monitoring certain aspects of health, especially for patients with specific risk factors. This monitoring typically includes checking for signs of bleeding, fluid retention, and assessing kidney function through follow-up tests like creatinine and BUN.

Q: Is it true that Fam is processed by the liver?

A: Yes, official clinical pharmacology documents confirm that Fam is largely metabolized (processed) in the liver. Once processed, the medication's inactive products are then primarily eliminated from the body via the kidneys.

Q: Are there specific times of the day recommended for taking Fam?

A: The recommended schedule for the oral tablet is typically four times a day. Regulatory information specifies that doses should be spaced approximately four to six hours apart to maintain consistent pain relief throughout the short treatment period.

Q: What should I do if I suspect an allergic reaction to Fam?

A: Severe allergic reactions are possible with this medication. Official patient information indicates that symptoms of a serious allergic reaction, such as difficulty breathing, hives, or swelling, require immediate emergency medical attention.

Q: Is Fam available over the counter, or does it require a prescription?

A: Fam is classified as a potent Non-Steroidal Anti-Inflammatory Drug (NSAID). Due to its strength and safety profile, all systemic formulations (the tablets, injections, and nasal spray) officially require a prescription.

Q: What is the typical duration of effect for a single dose of Fam?

A: The duration of the medication's effect is influenced by its half-life, which is the time it takes for half the drug to be eliminated from the body. In healthy adults, the half-life is documented to be between 4 and 6 hours.

Q: Are there any warnings about taking Fam before surgery?

A: Fam is formally contraindicated as a pain preventative before any major surgical procedure. This restriction is due to the documented potential for the medication to increase the risk of bleeding when hemostasis (blood clotting) is critical.

Q: Can Fam cause weight changes, either gain or loss?

A: Official lists of adverse events include reports of both weight change and fluid retention. The fluid retention in particular may be associated with weight gain in some patient reports.

Q: What are the known potential interactions between Fam and caffeine?

A: While not always explicitly listed in standard drug interaction sections, some evidence suggests that caffeine may increase the effects of Fam. This potential amplification is noted as potentially increasing the risk of adverse effects.

Q: Is Fam a medication that causes dependence or withdrawal symptoms?

A: Fam belongs to the NSAID pharmacological class and is not classified as a narcotic. Therefore, official sources confirm that the medication will not cause physical or mental dependence or withdrawal symptoms associated with opioid use.

Q: Does Fam affect fertility in men or women?

A: Adverse event reports include documentation of infertility related to the female reproductive system. Official advisories note that NSAIDs in general may affect the ability to become pregnant.

Q: Why is Fam not approved for all the conditions it is sometimes mentioned for online?

A: Fam's regulatory approval is highly specific, limited only to the short-term treatment of acute pain. Its use is specifically not indicated for chronic (long-term) pain or for minor pain conditions due to the documented safety risks associated with prolonged use.

Q: What is the longest period of time people typically take Fam?

A: Official prescribing information mandates that the total combined duration of systemic therapy must not exceed five days. While five days is the maximum, the exact length of time taken is determined by clinical need and is typically the shortest period required for acute pain management.

Q: Can Fam be taken by older adults, for instance, those over 65?

A: Official documents confirm that older adults (those over 65) can be prescribed the medication, but this population is at a greater risk for serious gastrointestinal adverse events. Therefore, a reduced dosage is specifically required for older patients.

Q: What kind of evidence supports the use of Fam for its intended purpose?

A: Evidence supporting the medication’s use for acute pain comes primarily from high-quality clinical studies, including Randomized Controlled Trials (RCTs) and systematic reviews. This body of research provides the basis for the medication's established role in short-term pain management.

Q: Is Fam approved for use in children or adolescents?

A: Official documents note that evidence is limited regarding the specific use and outcomes in pediatric populations (children 6–17 years). The medication is generally indicated for adults, and use in children must follow specific guidelines determined by a healthcare provider.

Q: Can Fam be taken if I have a history of kidney problems?

A: The medication is contraindicated for patients with advanced or severe kidney impairment. For individuals with other types of kidney impairment, a reduced dose is specifically required due to the slower elimination of the medication from the body.

Q: Is there any research on Fam's use during pregnancy?

A: Official safety information advises caution regarding use during pregnancy. While the medication is specifically contraindicated during labor and delivery, its use during the general period of pregnancy is only recommended when clearly necessary.

Q: Are there any non-drug products or foods known to interact with Fam?

A: Regulatory documents state that the oral tablet, when taken with a high-fat meal, can delay and reduce the achievement of its peak concentration. Additionally, patients are advised to inform their provider about all non-drug products, including supplements and herbal remedies, due to potential risks.

Q: Is Fam a short-term treatment or intended for long-term management?

A: Fam is formally classified as a short-term treatment. Official warnings mandate that the medication is not to be used for chronic (long-term) pain management, and the total duration of systemic use must not exceed five days.

Q: Why is Fam not recommended for people with certain heart conditions?

A: Official safety warnings highlight the risk of serious cardiovascular thrombotic events, such as heart attack and stroke. This inherent risk is the basis for the caution and potential non-recommendation of the medication for patients with certain pre-existing heart conditions.

Q: What is the classification of Fam—is it a Schedule-listed drug?

A: Fam is classified as a potent Non-Steroidal Anti-Inflammatory Drug (NSAID). Official sources confirm that Fam (ketorolac tromethamine) is not classified as a controlled substance or narcotic.

How should Fam be stored and disposed of?

How to Store and Dispose of Fam?

Official guidelines for storing Fam (Ketorolac tromethamine) mandate specific environmental controls and handling requirements.

Storage and Handling

The medication must be stored at controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF). It is essential to protect the medication from light, excess heat, and moisture. Fam should not be refrigerated or frozen. The product must be kept in the container it came in, tightly closed, and stored out of the sight and reach of children in a safe, high-up location.

Disposal Requirements

Do not keep outdated medicine. The preferred method for disposal is using a drug take-back program. If one is unavailable, dispose of the medication in household trash by first mixing it with an undesirable substance (such as dirt or used coffee grounds) and placing the mixture in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fam found in:

A-Z Index: